Zanubrutinib + Tislelizumab for B-Cell Lymphoma

Recruiting in Palo Alto (17 mi)

+224 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: BeiGene

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Breakthrough Therapy

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.

Research Team

Study Director

Principal Investigator

BeiGene

Eligibility Criteria

This trial is for people with B-cell malignancies who were in a previous BeiGene study. They should have stable vital signs, normal organ function, and agree to birth control if needed. It's not for those with severe heart failure, uncontrolled infections, or women who are pregnant or breastfeeding.

Inclusion Criteria

Platelets ≥ 50,000/mm3

Absolute neutrophil count ≥ 750/mm3

I am currently being treated with zanubrutinib.

Exclusion Criteria

Pregnant or lactating woman

Inability to comply with study procedures

I do not have an ongoing serious infection or one that needed IV antibiotics recently.

Treatment Details

Interventions

• Zanubrutinib (Bruton's Tyrosine Kinase (BTK) Inhibitor)

Trial Overview The trial tests long-term safety of Zanubrutinib alone or with Tislelizumab in patients previously enrolled in related studies. The focus is on those who may continue benefiting from Zanubrutinib after showing no progression of disease.

Participant Groups

Group I: Zanubrutinib in combination with Tislelizumab Experimental Treatment 2 Interventions

Participants to receive the combination as in the parent study (Australia Only)

Group II: Zanubrutinib (BGB-3111) Experimental Treatment 1 Intervention

All participants to receive open-label zanubrutinib

Zanubrutinib is already approved in China for the following indications:

Approved in China as Brukinsa for:

• Chronic lymphocytic leukemia (CLL)
• Small lymphocytic lymphoma (SLL)

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Oncology and Hematology Associates of Southwest Virginia, Inc Roanoke, VA

Oregon Health and Science University Portland, OR

Medical Oncology Associates Spokane, WA

University of Michigan Health System - Oncology Ann Arbor, MI

More Trial Locations

Who Is Running the Clinical Trial?

BeiGene

Lead Sponsor

Trials

216

Patients Recruited

32,500+